We are very pleased to share with you that WuXi and Foundation Medicine are partnering to offer the best-in-class comprehensive genomic profiling services to biopharmaceutical companies conducting clinical trials in China.
Based in Cambridge, MA, Foundation Medicine is a leading molecular information platform company with cutting-edge products such as FoundationOne®, a comprehensive genomic profiling assay commercially available for patients with cancer and covered by a US health plan. This collaboration enables WuXi to perform the laboratory component of FoundationOne® in China at the WuXi Genome Center, the first and only CLIA-certified laboratory in China. Our shared mission is to support our collaborators’ clinical R&D in China and help advance targeted cancer therapies through a better understanding of the underlying genomic drivers of cancer growth.
Please enjoy the press release: http://ir.wuxiapptec.com/phoenix.zhtml?c=212698&p=irol-newsArticle&ID=1980209, and let us know if you have any questions or inquiries.
Thank you for your continued support as we diligently strengthen our open-access capability and technology platform.